News

Triple therapy for COPD superior: study

Illustration of an Ellipta inhaler device created by the Interactive Content team at the University of Edinburgh for Chest Heart and Stroke Scotland (CHSS). https://www.flickr.com/photos/interactive-content/33763258421
Illustration of an Ellipta inhaler device created by the Interactive Content team at the University of Edinburgh for Chest Heart and Stroke Scotland (CHSS). https://www.flickr.com/photos/interactive-content/33763258421
New research published in the New England Journal of Medicine has shown triple therapy better reduces moderate/severe exacerbations compared with dual therapy Results from the IMPACT study, one of the largest ever studies conducted in patients with moderate to severe chronic obstructive pulmonary disease (COPD), has found use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) achieved superiority

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Flu jabs mandatory for aged care workers
Next Call for MM2018 abstracts

Related Posts